The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis
ABSTRACTAcute disseminated encephalomyelitis (ADEM) has been identified as an Adverse Event of Special Interest in the COVID-19 vaccine programme due to its long-standing temporal association with a wide range of other vaccines. Case reports of ADEM shortly following COVID−19 vaccination have now be...
| Autors principals: | , , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
Taylor & Francis Group
2024-12-01
|
| Col·lecció: | Human Vaccines & Immunotherapeutics |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2311969 |
| _version_ | 1827366344506474496 |
|---|---|
| author | Julia Stowe Jamie Lopez-Bernal Nick Andrews |
| author_facet | Julia Stowe Jamie Lopez-Bernal Nick Andrews |
| author_sort | Julia Stowe |
| collection | DOAJ |
| description | ABSTRACTAcute disseminated encephalomyelitis (ADEM) has been identified as an Adverse Event of Special Interest in the COVID-19 vaccine programme due to its long-standing temporal association with a wide range of other vaccines. Case reports of ADEM shortly following COVID−19 vaccination have now been documented. There were 217 ADEM admissions in 215 individuals in the period 8th December 2020 to 31st March 2023. An increased risk of ADEM following the first dose of ChAdOx1 vaccine was observed (relative incidence (RI) = 3.13, 95% Confidence Interval (CI) [1.56–6.25]) with a vaccine attributable risk of 0.39 per million doses. When doses 1 and 2 were combined this increased risk remained just significant (1.96 [95%CI 1.01–3.82]). No significant increased risk was observed with any other vaccine or dose. This small, elevated risk after the first dose of ChAdOx1-S vaccine demonstrates how large national electronic datasets can be used to identify very rare risks and provides reassurance that any risk of ADEM following the ChAdOx1-S COVID-19 vaccination is extremely small. Given the rarity of this risk, further studies in settings with access to data on large populations should be carried out to verify these findings. |
| first_indexed | 2024-03-08T08:48:39Z |
| format | Article |
| id | doaj.art-bac8e72b94774a95bceb51a79ae2fade |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-08T08:48:39Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-bac8e72b94774a95bceb51a79ae2fade2024-02-01T13:04:39ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2311969The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysisJulia Stowe0Jamie Lopez-Bernal1Nick Andrews2Immunisation Division, UK Health Security Agency, London, UKImmunisation Division, UK Health Security Agency, London, UKImmunisation Division, UK Health Security Agency, London, UKABSTRACTAcute disseminated encephalomyelitis (ADEM) has been identified as an Adverse Event of Special Interest in the COVID-19 vaccine programme due to its long-standing temporal association with a wide range of other vaccines. Case reports of ADEM shortly following COVID−19 vaccination have now been documented. There were 217 ADEM admissions in 215 individuals in the period 8th December 2020 to 31st March 2023. An increased risk of ADEM following the first dose of ChAdOx1 vaccine was observed (relative incidence (RI) = 3.13, 95% Confidence Interval (CI) [1.56–6.25]) with a vaccine attributable risk of 0.39 per million doses. When doses 1 and 2 were combined this increased risk remained just significant (1.96 [95%CI 1.01–3.82]). No significant increased risk was observed with any other vaccine or dose. This small, elevated risk after the first dose of ChAdOx1-S vaccine demonstrates how large national electronic datasets can be used to identify very rare risks and provides reassurance that any risk of ADEM following the ChAdOx1-S COVID-19 vaccination is extremely small. Given the rarity of this risk, further studies in settings with access to data on large populations should be carried out to verify these findings.https://www.tandfonline.com/doi/10.1080/21645515.2024.2311969Acute disseminated encephalomyelitis (ADEM)self-controlled case-seriesCOVID-19 vaccine safety |
| spellingShingle | Julia Stowe Jamie Lopez-Bernal Nick Andrews The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis Human Vaccines & Immunotherapeutics Acute disseminated encephalomyelitis (ADEM) self-controlled case-series COVID-19 vaccine safety |
| title | The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis |
| title_full | The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis |
| title_fullStr | The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis |
| title_full_unstemmed | The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis |
| title_short | The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis |
| title_sort | risk of acute disseminated encephalomyelitis adem following covid 19 vaccination in england a self controlled case series analysis |
| topic | Acute disseminated encephalomyelitis (ADEM) self-controlled case-series COVID-19 vaccine safety |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2311969 |
| work_keys_str_mv | AT juliastowe theriskofacutedisseminatedencephalomyelitisademfollowingcovid19vaccinationinenglandaselfcontrolledcaseseriesanalysis AT jamielopezbernal theriskofacutedisseminatedencephalomyelitisademfollowingcovid19vaccinationinenglandaselfcontrolledcaseseriesanalysis AT nickandrews theriskofacutedisseminatedencephalomyelitisademfollowingcovid19vaccinationinenglandaselfcontrolledcaseseriesanalysis AT juliastowe riskofacutedisseminatedencephalomyelitisademfollowingcovid19vaccinationinenglandaselfcontrolledcaseseriesanalysis AT jamielopezbernal riskofacutedisseminatedencephalomyelitisademfollowingcovid19vaccinationinenglandaselfcontrolledcaseseriesanalysis AT nickandrews riskofacutedisseminatedencephalomyelitisademfollowingcovid19vaccinationinenglandaselfcontrolledcaseseriesanalysis |